Login to Your Account



Financings NEWS

LONDON – Biogeneration Ventures has exceeded the €50 million (US$56.7 million) target set for its third early stage fund, announcing a €66 million (US$74.9 million) close, with plans to push on to a final close of €75 million before the end of the year.

DUBLIN – Mitoconix Bio Ltd., an Israeli startup commercializing science that emerged from Stanford University's School of Medicine, raised $20 million in series A funding to take forward a first-in-class inhibitor of mitochondrial division for treating Huntington's disease and other neurodegenerative conditions.

With two phase III studies of lead compound, KPI-121 1.0 percent, in the books to treat inflammation and pain following cataract surgery, Kala Pharmaceuticals Inc. looked to the public markets to fund pre-commercialization activities for the nanoparticle-based therapy by filing for an IPO of $86.25 million.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: